{
    "clinical_study": {
        "@rank": "165020", 
        "brief_summary": {
            "textblock": "To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses\n      along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in\n      AIDS patients TMTX is an experimental new drug which is effective for treatment of PCP, but\n      has been given to only a few patients. Therefore it is not certain if TMTX is better, the\n      same as, or not as effective as conventional drugs against PCP."
        }, 
        "brief_title": "A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP", 
        "completion_date": {
            "#text": "April 1989", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "detailed_description": {
            "textblock": "TMTX is an experimental new drug which is effective for treatment of PCP, but has been given\n      to only a few patients. Therefore it is not certain if TMTX is better, the same as, or not\n      as effective as conventional drugs against PCP.\n\n      Increasing doses of TMTX are used in combination with LCV as initial treatment for PCP in 50\n      AIDS patients. Doses are increased for 21 days on a once daily and then a twice daily basis.\n      Dose escalations occur in subsequent groups of patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patient must:\n\n          -  Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current\n             episode. PCP must be documented by observation of > 1 cluster of organisms in sputum,\n             bronchial secretion, or lung tissue.\n\n          -  Have clinical symptoms of respiratory disease or radiologic abnormalities.\n\n        Exclusion Criteria\n\n          -  Patient cannot have significant emotional disorder.\n\n        Concurrent Medication: Excluded:\n\n          -  Drugs likely to be bone marrow toxic.\n\n          -  Investigational drugs.\n\n        Prior Medication:  Excluded:\n\n          -  Three patients in each group cannot have had zidovudine (AZT) for at least 2 months\n             prior to administration of trimetrexate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000998", 
            "org_study_id": "ACTG 018", 
            "secondary_id": "10994"
        }, 
        "intervention": [
            {
                "intervention_name": "Trimetrexate glucuronate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Leucovorin calcium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antineoplastic Agents", 
                "Trimetrexate", 
                "Folic Acid Antagonists", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "keyword": [
            "Trimetrexate", 
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Injections, Intravenous", 
            "Leucovorin", 
            "Dose-Response Relationship, Drug", 
            "Drug Therapy, Combination", 
            "Folic Acid Antagonists", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome", 
            "Antineoplastic Agents"
        ], 
        "lastchanged_date": "December 17, 2012", 
        "link": {
            "description": "Click here for more information about Trimetrexate glucuronate", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=183"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "Los Angeles County - USC Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics", 
        "overall_official": {
            "last_name": "Masur H", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "2136905", 
            "citation": "Sattler FR, Allegra CJ, Verdegem TD, Akil B, Tuazon CU, Hughlett C, Ogata-Arakaki D, Feinberg J, Shelhamer J, Lane HC, et al. Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. J Infect Dis. 1990 Jan;161(1):91-6."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000998"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }, 
    "geocoordinates": {
        "Los Angeles County - USC Med Ctr": "34.052 -118.244"
    }
}